I reckon that if someone is somehow able to invent and trial a new FTO inhibitor ahead of Xantrene (which is massively unlikely) then someone else will instantly snap up Xantrene to ensure they're quickly to market - so it's a win either way.
Alternatively, IMHO should someone even get one into the clinic then someone else will rush Xantrene to get to market first.
A friend of mine strategised this last May, and I tend to agree with him.
- Forums
- ASX - By Stock
- Ann: Trading Halt
I reckon that if someone is somehow able to invent and trial a...
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.72 |
Change
-0.010(0.58%) |
Mkt cap ! $301.5M |
Open | High | Low | Value | Volume |
$1.76 | $1.77 | $1.72 | $112.3K | 64.64K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2227 | $1.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.73 | 1060 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2227 | 1.715 |
1 | 1200 | 1.710 |
1 | 1000 | 1.705 |
2 | 5031 | 1.700 |
1 | 990 | 1.690 |
Price($) | Vol. | No. |
---|---|---|
1.725 | 100 | 1 |
1.735 | 1300 | 2 |
1.750 | 400 | 1 |
1.775 | 4801 | 1 |
1.780 | 3000 | 1 |
Last trade - 13.24pm 23/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online